Angela Castellanos Rodriguez
Fred Hutch/University of Washington Cancer Consortium
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Angela Castellanos Rodriguez as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:58 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07673341 · [18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed CholangiocarcinomaUniversity of Washington · recruiting · Cholangiocarcinoma · principal investigator
- Ph2NCT06526299 · Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing DiseaseUniversity of Washington · recruiting · Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:58 UTC. The ranking covers the 200 most relevant of 32 PubMed records, and a shared surname and initials can bring in a namesake. All 32 on PubMed
- 472 citationsRCR 12.0
- 358 citationsRCR 12.0
- Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.J Natl Cancer Inst · 2011256 citationsRCR 7.9
- Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.Lancet Oncol · 2015242 citationsRCR 9.2
- Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.Cancer Prev Res (Phila) · 2013183 citationsRCR 5.7
- Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial.J Natl Cancer Inst · 2020173 citationsRCR 8.9
- Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial.Lancet Oncol · 2011152 citationsRCR 4.6
- Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica.Cancer Discov · 2011137 citationsRCR 4.0
- 136 citationsRCR 3.9
- 116 citationsRCR 5.0